IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma
Open Access
- 5 March 2021
- journal article
- research article
- Published by Elsevier BV in World Allergy Organization Journal
- Vol. 14 (3), 100520
- https://doi.org/10.1016/j.waojou.2021.100520
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Relevance of TH2 Markers in the Assessment and Therapeutic Management of Severe Allergic Asthma: A Real-Life PerspectiveJournal of Investigational Allergology and Clinical Immunology, 2020
- Precision Medicine in Asthma-Using Phenotypes to Understand Endotypes That Lead Us to New Therapeutic OptionsThe Journal of Allergy and Clinical Immunology: In Practice, 2020
- Management of severe asthma: a European Respiratory Society/American Thoracic Society guidelineEuropean Respiratory Journal, 2020
- Toward clinically applicable biomarkers for asthma: An EAACI position paperAllergy, 2019
- Severe Asthma Phenotypes — How Should They Guide Evaluation and Treatment?The Journal of Allergy and Clinical Immunology: In Practice, 2017
- Particularities of allergy in the TropicsWorld Allergy Organization Journal, 2016